Previous 10 | Next 10 |
MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive...
Syneos Health (SYNH) announced the acquisition of Illingworth Research Group, a leading provider of clinical research home health services.The acquisition adds new scale and capabilities to Syneos Health’s decentralized clinical trial solutions.“Joining Syneos Health offers...
MORRISVILLE, N.C., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of Illingworth Research Group™, a leading provider of clinical research home health service...
Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance. Subsequent to the Q3 results, the company hosted an analyst and investor event, providing a longer-term growth target. If Syneos can meet its 2023 targets, the company is cheap at the current levels. ...
MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previously announced acquisition of Synteract, a leading full-service CRO focuse...
Baird is raising its price target to a Street high on its "first contender for the 2021 Best Idea List." That's biopharmaceutical solutions company Syneos Health (SYNH), where the firm is reiterating its Outperform rating with a Fresh Pick designation following the company's analyst/investor ...
The following slide deck was published by Syneos Health, Inc. in conjunction with this event. For further details see: Syneos Health (SYNH) Investor Presentation - Slideshow
Unique Product Development Model Delivers Accelerated Growth Presentation Begins at 9:00 A .M. ET on Tuesday, December 8 MORRISVILLE, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutic...
VBI Vaccines ([[VBIV]] +1.2%) and Syneos Health ([[SYNH]] -0.8%)have entered into commercialization partnership for the VBI’s 3-antigen prophylactic hepatitis B ((HBV)) vaccine in the U.S., Europe, and Canada, pending regulatory approvals.VBI and Syneos Health have ...
- VBI and Syneos Health partner to prepare for commercial launch of VBI’s 3-antigen hepatitis B vaccine in the U.S., Europe, and Canada, pending regulatory approvals - Syneos Health selected for their robust and innovative commercialization experience and deep vaccine expertise...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...